PT  - JOURNAL ARTICLE
AU  - Mason, Thomas
AU  - Whitston, Matt
AU  - Hodgson, Jack
AU  - Watkinson, Ruth E
AU  - Lau, Yiu-Shing
AU  - Abdulrazeg, Omnia
AU  - Sutton, Matt
TI  - Effects of BNT162b2 mRNA vaccine on Covid-19 infection and hospitalisation among older people: matched case control study for England
AID  - 10.1101/2021.04.19.21255461
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.19.21255461
4099  - http://medrxiv.org/content/early/2021/04/22/2021.04.19.21255461.short
4100  - http://medrxiv.org/content/early/2021/04/22/2021.04.19.21255461.full
AB  - Background The BNT162b2 mRNA vaccine has been shown to be effective at preventing serious Covid-19 events in clinical trials. There is less evidence on effectiveness in real-world settings, especially for older people. The rapid roll-out of the NHS vaccination programme in England based on age thresholds offers an opportunity to make unbiased comparisons of outcomes between vaccinated and unvaccinated populations.Methods and Findings We matched older (aged 80-83 years) vaccine recipients with younger (aged 76-79 years) persons not yet eligible to receive the vaccine on gender, area of residence, area deprivation, health status, living arrangements, acute illness, and history of seasonal flu vaccination. We also adjusted for the over-representation of Covid-19 positive individuals in the control population because eligibility for vaccination required no Covid-19 symptoms in the previous two weeks. The study population included 170,226 individuals between the ages of 80 and 83 years from community settings outside care homes who received one dose of BNT162b2 mRNA between the 15th and 20th December 2020 and were scheduled a second dose 21 days later.We found emergency hospital admissions were 51.0% (95% confidence interval: 19.9% to 69.5%) lower and positive Covid-19 tests were 55.2% (40.8% to 66.8%) lower for vaccinated individuals compared to matched controls 21 to 27 days after first vaccination. Emergency admissions were 75.6% (52.8% to 87.6%) lower and positive Covid-19 tests were 70.1% (55.1% to 80.1%) lower 35 to 41 days after first vaccination when 79% of participants had received a second dose within 26 days of their first dose.Conclusions Receipt of the BNT162b2 mRNA vaccine is effective at reducing Covid-19 hospitalisations and infections. The nationwide vaccination of older adults in England with the BNT162b2 mRNA vaccine reduced the burden of Covid-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementTM, JH, OA and MW are funded by NHS England & NHS Improvement. RW is funded by The University of Manchester. MS is funded by NIHR Applied Research Collaboration for Greater Manchester. YL is funded by the National Institute for Health Research (NIHR) Policy Research Programme via the Policy Research Unit in Health and Social Care Systems and Commissioning. MS is a NIHR Senior Investigator. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Surveillance of COVID-19 testing and vaccination is undertaken under Regulation 3 of The Health Service (Control of Patient Information) Regulations 2002 to collect confidential patient information (http://www.legislation.gov.uk/uksi/2002/1438/regulation/3/made) under Sections 3(i) (a) to (c), 3(i)(d) (i) and (ii) and 3(3). Review by the Heath Research Authority identified no regulatory issues with this evaluation, and ethical review is not a requirement for this study. Data analysis was facilitated under Control of patient information (COPI) notice (https://digital.nhs.uk/coronavirus/coronavirus-covid-19-response-information-governance-hub/control-of-patient-information-copi-notice). Informed consent was not required for the study. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in the study are not publicly available and may be obtained via NHS Digital (https://digital.nhs.uk/services/data-access-request-service-dars). The analysis scripts used for the evaluation are available at https://github.com/NHSEI-Analytics/nhs_covid19_effectiveness. https://github.com/NHSEI-Analytics/nhs_covid19_effectiveness